| 초록 |
Nitric oxide (NO) has been known to play important roles in the control of tumor progression. Recent researches have shown the potential of NO in a direct use in combination with chemotherapeutic agents to enhance its cytotoxicity for a variety of cancers. However, the direct delivery of NO into tumor cells is problematic, because NO has an extremely short half-life in the body. Herein, we developed NO-releasing hyaluronic acid nanoparticles (GSNO-HANPs). The GSNO-HANPs in an extracellular environment (pH 7.4, ascorbic acid = 8 μM) showed a retarded release pattern of NO. In contrast, the GSNO-HANPs demonstrated the much faster NO release at an intracellular environment (pH 5.0, ascorbic acid = 50 mM). We verified in vitro therapeutic efficacy using the GSNO-HANPs as an adjuvant for anticancer activity of doxorubicin (DOX). The released NO from the GNSO-HANPs improved the therapeutic activity of DOX. The GSNO-HANPs may successfully serve as novel intracellular delivery carriers of NO. |
